Skip to content

Evolved metabolites already treat many cancers. We are discovering the next generation.

Many of the pathways that drive cancer growth are targeted by natural products – such as topoisomerase inhibitors, tubulin inhibitors, DNA damaging agents, and more. These molecules evolved to inhibit cell growth and are valuable anti-cancer agents. New technologies have revealed the next-generation of targeted therapies, particularly as novel payloads for antibody drug conjugates, for cancer treatments.


Our diverse team combines computational biology and experimental investigation with deep expertise at the intersection of these fields.

Meet our team on LinkedIn

Learn More

Board of Directors

David Goeddel, PhD, Chairman

Managing Partner, The Column Group

Maureen Hillenmeyer, PhD

CEO & Co-Founder, Hexagon Bio

Juan Jaen, PhD

President, Arcus Biosciences

Jakob Loven, PhD

Managing Partner, Nextech Invest

Brian Naughton, PhD

Chief Technology Officer & Co-Founder, Hexagon Bio

Millie Ray, PhD

Partner, The Column Group

Alex Kolicich

Founding Partner, 8VC

Scientific Advisory Board

John Josey, PhD

Venture Partner, The Column Group

Steven McKnight, PhD

Distinguished Chair in Basic Biomedical Research, UT Southwestern Medical Center

Marnix Medema, PhD

Professor of Bioinformatics at Wageningen University & Research

Frank C. Schroeder, PhD

Professor, Boyce Thompson Institute
Professor, Department of Chemistry and Chemical Biology, Cornell University

Anthony Tolcher, MD

NEXT Oncology, CEO, Founder and Director of Clinical Research


We have assembled leading technology- and life science-focused investors who believe in and support our ambition to become the world-leading company in developing human therapeutics from metagenomes.

CPP Investments

Partner with us

If you are interested in partnering with us, please get in touch.

Contact Us